Drug Details

General Information of the Drug (ID: DR6236)
Name
Nalidixic acid
Synonyms
nalidixic acid; 389-08-2; Nalidixin; Nevigramon; Nalidixate; Uronidix; NegGram; Innoxalon; Nalidixan; Nalitucsan; Sicmylon; Unaserus; Nalidic acid; Nalidixinic acid; Wintomylon; Dixiben; Dixinal; Jicsron; Nalurin; Naxuril; Nogram; Urisal; Cybis; Nalix; 1-Ethyl-7-methyl-4-oxo-1,4-dihydro-1,8-naphthyridine-3-carboxylic acid; Nalidicron; Betaxina; Kusnarin; Narigix; Nicelate; Specifen; Specifin; Uralgin; Uriclar; Urodixin; Negram; Poleon; Uriben; Uroman; Uroneg; Uropan; Acide nalidixique; Eucistin; Acide nalidixico; Acido nalidixico; Acidum nalidixicum; 1-Ethyl-1,4-dihydro-7-methyl-4-oxo-1,8-naphthyridine-3-carboxylic acid; NSC-82174; Nalidixane; WIN 18,320; 1,4-Dihydro-1-ethyl-7-methyl-4-oxo-1,8-naphthyridine-3-carboxylic acid; 1-ethyl-7-methyl-4-oxo-1,8-naphthyridine-3-carboxylic acid; 3-Carboxy-1-ethyl-7-methyl-1,8-naphthyridin-4-one; NCI-C56199; MFCD00006884; 1,8-Naphthyridine-3-carboxylic acid, 1-ethyl-1,4-dihydro-7-methyl-4-oxo-; 3-Carboxy-1-ethyl-7-methyl-1,8-naphthidin-4-one; UNII-3B91HWA56M; 1-Ethyl-7-methyl-1,4-dihydro-1,8-naphthyridin-4-one-3-carboxylic acid; 1-Aethyl-7-methyl-1,8-naphthyridin-4-on-3-karbonsaeure; Nalidixic acid (NegGram); MLS000028504; 3B91HWA56M; Acide 1-etil-7-metil-1,8-naftiridin-4-one-3-carbossilico; Win 18320; CHEBI:100147; 1-Ethyl-7-methyl-4-oxo-1,4-dihydro-[1,8]naphthyridine-3-carboxylic acid; NSC82174; NCGC00018181-08; SMR000058264; Wintron; DSSTox_CID_912; 1,4-Dihydro-1-ethyl-7-methyl-1,8-naphthyridin-4-one-3-carboxylic acid; Acido nalidissico; Nalidixic acid, 99.5%; DSSTox_RID_75859; DSSTox_GSID_20912; Acido nalidissico [DCIT]; Acide nalidixico [Italian]; Acide nalidixique [French]; Nalidixic; Acide nalidixique [INN-French]; Acido nalidixico [INN-Spanish]; Acidum nalidixicum [INN-Latin]; 1,8-Naphthyridine-3-carboxylic acid,1-ethyl-1,4-dihydro-7-methyl-4-oxo-; CAS-389-08-2; NegGram (TN); CCRIS 2365; HSDB 3241; EINECS 206-864-7; BRN 0750515; Innoxalomn; Eucisten; nalidixic-acid; SR-01000003086; 1-Aethyl-7-methyl-1,8-naphthyridin-4-on-3-karbonsaeure [German]; Acide 1-etil-7-metil-1,8-naftiridin-4-one-3-carbossilico [Italian]; WIN-18320; WIN 183203; CHEMBL5; Spectrum_000918; Nalidixic acid [USAN:USP:INN:BAN:JAN]; Maybridge1_007101; Opera_ID_1064; Prestwick0_000187; Prestwick1_000187; Prestwick2_000187; Prestwick3_000187; Spectrum2_001360; Spectrum3_000075; Spectrum4_000817; Spectrum5_001540; Nalidixic acid, >=98%; UPCMLD-DP129; N-1200; NCIOpen2_004342; Lopac0_000837; Oprea1_010545; SCHEMBL21736; BSPBio_000113; BSPBio_001889; KBioGR_001333; KBioSS_001398; 5-25-07-00384 (Beilstein Handbook Reference); MLS001148578; MLS002303041; MLS004820190; MLS006011875; 1-ethyl-7-methyl-4-oxo-1; BIDD:GT0529; DivK1c_000058; SPECTRUM1500756; SPBio_001579; SPBio_002034; BPBio1_000125; DTXSID3020912; UPCMLD-DP129:001; BDBM21691; HMS500C20; HMS561K17; KBio1_000058; KBio2_001398; KBio2_003966; KBio2_006534; KBio3_001109; ZINC57421; NINDS_000058; HMS1921G10; HMS2092K04; HMS2232H24; HMS3259O13; HMS3374G11; HMS3656K05; Pharmakon1600-01500756; Nalidixic acid (JP17/USP/INN); Nalidixic acid, analytical standard; ALBB-021275; HY-B0398; Tox21_110835; Tox21_201477; Tox21_302754; ANW-42195; BBL012279; CCG-39298; NSC757432; SBB002146; STK735579; 1,8-Naphthyridine-3-carboxylicacid, 1-ethyl-1,4-dihydro-7-methyl-4-oxo-; 1-Ethyl-1,4-dihydro-7-methyl-4-oxo-1,8-naphthyridine-3-carboxilic acid; AKOS000120074; Tox21_110835_1; DB00779; MCULE-6808033849; NC00494; NSC-757432; SDCCGSBI-0050814.P004; IDI1_000058; NCGC00018181-01; NCGC00018181-02; NCGC00018181-03; NCGC00018181-04; NCGC00018181-05; NCGC00018181-06; NCGC00018181-07; NCGC00018181-09; NCGC00018181-10; NCGC00018181-12; NCGC00018181-13; NCGC00021730-03; NCGC00021730-04; NCGC00021730-05; NCGC00021730-06; NCGC00021730-07; NCGC00256581-01; NCGC00259028-01; AK163550; AS-13289; H816; NCI60_041807; SMR004703506; WLN: T66 BN EV JNJ B2 DVQ I1; SBI-0050814.P003; AB0013282; DB-049349; 1, 1-ethyl-1,4-dihydro-7-methyl-4-oxo-; BB 0242389; FT-0603390; N0490; S2328; SW219624-1; 1-Ethyl-1,8-naphthyridine-3-carboxilic acid; 1-Ethyl-1,8-naphthyridine-3-carboxylic acid; Nalidixic acid 100 microg/mL in Acetonitrile; VU0239598-6; C05079; D00183; K-8443; Nalidixic acid, meets USP testing specifications; 389N082; Q281082; SR-01000003086-4; SR-01000003086-6; BRD-K47886988-323-03-0; Nalidixic acid, Antibiotic for Culture Media Use Only; SR-01000003086-10; F0850-6751; Z256708444; 1-Ethyl-7-methyl-1,8-naphthyridin-4-one-3-carboxylic acid; 1-ethyl-7-methyl-4-oxo-[1,8]naphthyridine-3-carboxylic acid; Nalidixic acid, European Pharmacopoeia (EP) Reference Standard; Nalidixic acid, United States Pharmacopeia (USP) Reference Standard; 1-Ethyl-7-methyl-4-oxo-1,4-dihydro-[1,8]naph thyridine-3-carboxylic acid; 1-ethyl-7-methyl-4-oxohydropyridino[2,3-b]pyridine-3-carboxylic acid; N-benzyl-4-[(5-cyclobutyl-1,2,4-oxadiazol-3-yl)methyl]-N-ethyl-3-oxo-3,4-dihydro-2H-1,4-benzoxazine-6-sulfonamide
    Click to Show/Hide
Molecular Type
Small molecule
Disease Urinary tract infection [ICD-11: GC08] Approved [1]
Structure
Click to Download Mol
2D MOL

3D MOL

    Click to Show/Hide the Molecular Information and External Link(s) of This Natural Product
Formula
C12H12N2O3
PubChem CID
4421
Canonical SMILES
CCN1C=C(C(=O)C2=C1N=C(C=C2)C)C(=O)O
InChI
1S/C12H12N2O3/c1-3-14-6-9(12(16)17)10(15)8-5-4-7(2)13-11(8)14/h4-6H,3H2,1-2H3,(H,16,17)
InChIKey
MHWLWQUZZRMNGJ-UHFFFAOYSA-N
CAS Number
CAS 389-08-2
ChEBI ID
CHEBI:100147
TTD Drug ID
D07JGT
DrugBank ID
DB00779
Combinatorial Therapeutic Effect(s) Validated Clinically or Experimentally
    α. A List of Natural Product(s) Able to Enhance the Efficacy of This Drug
          Camellia sinensis      Camellia sinensis     Click to Show/Hide the Molecular Data of This NP
                 Achieving Therapeutic Synergy     Click to Show/Hide
                    Representative Experiment Reporting the Effect of This Combination [2]
                    Detail(s)  Combination Info  click to show the detail info of this combination
                    In-vitro Model Staphylococcus aureus Microorganism model Staphylococcus aureus
Streptococcus pyogenes Microorganism model Streptococcus pyogenes
Escherichia coli Microorganism model Escherichia coli
Salmonella enterica serovar Typhi Microorganism model Salmonella enterica
Shigella species Microorganism model Shigella
Salmonella Paratyphi A Microorganism model Salmonella Paratyphi
Pseudomonas aeuginosa Microorganism model Pseudomonas aeruginosa
Acinetobacter baumannii Microorganism model Acinetobacter baumannii
Klebseilla pneumoniae Microorganism model Klebseilla pneumoniae
Citrobacter freuendii Microorganism model Citrobacter freuendii
Enterobacter cloacae Microorganism model Enterobacter cloacae
Bacillus subtilis Microorganism model Bacillus subtilis
Streptococcus pneumoniae Microorganism model Streptococcus pneumoniae
Micrococcus Microorganism model Micrococcus
Helicobacter pylori Microorganism model Helicobacter pylori
Campylobacter jejuni Microorganism model Campylobacter jejuni
Pasteurella multocida Microorganism model Pasteurella multocida
                    Experimental
                    Result(s)		 When Camellia sinensis was combined with nalidixic acid, it was able to inhibit S. Typhi at sub-MIC levels.
Target and Pathway
Target(s) DNA topoisomerase II (TOP2)  Molecule Info  [3]
References
Reference 1 FDA Approved Drug Products from FDA Official Website. 2009. Application Number: (ANDA) 071919.
Reference 2 Synergistic antimicrobial activity of Camellia sinensis and Juglans regia against multidrug-resistant bacteria. PLoS One. 2015 Feb 26;10(2):e0118431.
Reference 3 Activity of fluoroquinolone antibiotics against Plasmodium falciparum in vitro. Antimicrob Agents Chemother. 1988 Aug;32(8):1182-6.
 Download Picture         KEGG Link